Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)


Creative Commons License

Gibson C. M. , Chi G., Halaby R., Korjian S., Daaboul Y., Jain P., ...More

CIRCULATION, vol.135, no.7, pp.648-655, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 135 Issue: 7
  • Publication Date: 2017
  • Doi Number: 10.1161/circulationaha.116.025427
  • Title of Journal : CIRCULATION
  • Page Numbers: pp.648-655
  • Keywords: anticoagulants, cardiology, cardiovascular diseases, intracranial hemorrhages, stroke, thrombosis, WARFARIN, OUTCOMES, CARE

Abstract

BACKGROUND: Stroke is a morbid and potentially mortal complication among patients hospitalized with acute medical illness. The potential of extended-duration thromboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of stroke compared with standard-dose enoxaparin in this population was assessed in this retrospective APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).